.png)
Patient-Centric
Drug Discovery
Accelerated by AI
MISSION
Leveraging AI and patient data to develop medicines with greater probabilities of success – faster.
Archetype™ is an AI-native biotech company founded by genomic data science veterans and working with clinician leaders and scientific experts. Archetype is pioneering the use of AI for generative chemogenomics – enabling the virtual screening of billions of potential drugs against patient clinical outcomes per day.
The disease-agnostic Archetype platform has been deployed in metastatic castration-resistant prostate cancer (mCRPC), early-stage lung adenocarcinoma (esLUAD), metastatic melanoma, and idiopathic pulmonary fibrosis (IPF), and has accurately predicted the outcomes of clinical trials and the impact of drugs in these diseases.
Archetype is partnering across the healthcare and life sciences ecosystem to rapidly discover and develop
patient-driven therapeutics.
OUR SCIENCE
Patients are at the foundation of every Archetype drug discovery program
It starts with patients and their data
For a given disease, we use clinicogenomic data from patients with pressing unmet medical need to build computer models that characterize biological states associated with a continuum of relatively good to bad outcomes.
Using deep learning and generative AI, we build computer models that generate readouts describing how molecules not utilized before in the disease of interest will shift these biological states.
Massive virtual phenotypic screening
We use these models to screen in just days billions of drug-like molecules, in silico, to identify those that are most likely to improve patient clinical outcomes.
We avoid the pitfalls of assuming that the complete effect of a therapeutic candidate occurs at only one target by using broader biological states – such as the expression of many genes – as our lingua franca in the screening process.
The Archetype platform identified in silico pre-lead molecules and predicted clinical trial outcomes for metastatic castrate-resistant prostate cancer (mCRPC) and early-stage lung adenocarcinoma (esLUAD).
OUR EXPERTISE
Archetype in Numbers
Our discovery process is tied to patient clinical outcomes from the outset, providing a built-in biomarker program and clinical relevance.
Patient-Data Driven
Disease-drug dynamics are more complex than a single drug-target interaction – we generate readouts that incorporate this complexity.
Generative Biology
We virtually screen billions of drug-like molecules -- and automated chemist-like modifications of those molecules -- against patient clinical outcomes.
Massive Virtual Screening
WHY ARCHETYPE
1
Guinness World Record winning team member
4
Disease areas with newly discovered molecules
~50
Co-founders' combined years in genomics
Billions
Drug-like small molecules screened